PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026JAMA Network Open2 citationsOpen Access

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes

FHFu-Chih HsiaoTHTzyy-Jer HsuYHYu-Jui Hsieh

Key Points

  • Recurrent limb events, cardiovascular events, and all-cause mortality were significantly lower with GLP-1 RAs.
  • Treatment with GLP-1 receptor agonists led to reduced risks over DPP-4 inhibitors in a high-risk group.
  • Cohort analysis of patients with diabetes previously experiencing major adverse limb events.
  • Findings support prioritizing GLP-1 RA use for better outcomes in this population.

Abstract

In this nationwide cohort study of patients with diabetes and prior MALEs, treatment with GLP-1 RAs was associated with significantly lower risks of recurrent limb events, cardiovascular events, all-cause mortality, and kidney disease progression compared with DPP-4 inhibitors. These findings support the preferential use of GLP-1 RAs for secondary prevention in this high-risk population.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hsiao et al. (2026) studied this question.

synapsesocial.com/papers/69a75cd8c6e9836116a260e4https://doi.org/10.1001/jamanetworkopen.2025.55952
Ask AI
Helpful
Bookmark
Share
View Full Paper